GABAergic Ligands Without Ester Linkages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current benzodiazepine derivatives used as GABAergic receptor subtype selective ligands often contain ester linkages, making them susceptible to hydrolysis by esterases in vivo, which reduces their efficacy and stability.
Innovation Solution
Development of compounds, such as those represented by formulas (I), (II), and (III), which lack ester linkages and are designed to selectively bind to alpha 2, alpha 3, or alpha2/alpha3 GABAergic receptor subtypes, thereby minimizing hydrolysis and maintaining therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzodiazepine derivatives contain ester linkages to achieve selective binding to GABAergic receptor subtypes, then receptor subtype selectivity is improved, but stability in vivo deteriorates due to hydrolysis by esterases
Solution Approach 1:
The patent removes the ester linkage from the benzodiazepine derivative structure, extracting the problematic functional group that causes hydrolysis while retaining the core pharmacophore necessary for receptor binding. This eliminates the vulnerability to esterase-mediated degradation while preserving receptor subtype selectivity through the remaining structural features.
Solution Approach 2:
The patent modifies the chemical structure by changing the functional group at the ester position to a non-hydrolyzable alternative. This parameter change in molecular structure transforms the compound from one susceptible to enzymatic degradation into a stable molecule that maintains its pharmacological activity without undergoing hydrolysis in vivo.
2Reliability
If benzodiazepine derivatives are designed for high receptor subtype selectivity, then therapeutic efficacy is improved, but susceptibility to hydrolysis increases due to ester linkages
Solution Approach 1:
The patent converts the harmful effect of ester linkages by replacing them with stable isosteric groups. This transformation eliminates the harmful hydrolysis while maintaining or even improving the therapeutic efficacy through enhanced stability and prolonged duration of action at the target receptor subtypes.
Solution Approach 2:
The patent replaces the labile ester linkage with a stable, non-hydrolyzable structural element, effectively creating a 'permanent' bond that does not require metabolic processing. This eliminates the short-lived nature of ester-containing compounds and provides sustained therapeutic effect.
3Adaptability or versatility
If ester linkages are present in benzodiazepine derivatives, then molecular flexibility is improved for receptor binding, but metabolic stability deteriorates due to esterase hydrolysis
Solution Approach 1:
The patent extracts the ester linkage from the molecular structure, removing the source of metabolic instability. The remaining structure maintains adequate flexibility through other rotatable bonds and structural features, preserving the ability to adopt conformations necessary for receptor binding while eliminating the metabolic vulnerability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate selective binding to GABAergic receptor subtypes, providing effective treatment for anxiety disorders, depression, epilepsy, schizophrenia, and neuropathic pain with reduced sedative and muscle-relaxant side effects, while maintaining stability in vivo.
Implementation Method 1
These compounds are useful as GABAergic receptor subtype selective ligands
Implementation Method 2
Current benzodiazepine derivatives used as GABAergic receptor subtype selective ligands often contain ester linkages, making them susceptible to hydrolysis by esterases in vivo
Data Source
AI summary
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.